Cachexia is a syndrome characterized by significant weight loss, muscle atrophy, and fatigue that occurs in chronic diseases. It is often associated with conditions such as cancer, AIDS, heart failure, and chronic obstructive pulmonary disease (COPD).
Pathophysiology Cachexia is mediated by various inflammatory cytokines, which contribute to the development and progression of the syndrome. The key mediators include:
- TNF-α (Tumor Necrosis Factor-alpha)
- IFN-γ (Interferon-gamma)
- IL-1 (Interleukin-1)
- IL-6 (Interleukin-6)
Impact on Chronic Diseases
- Cancer: Cachexia can exacerbate the patient’s condition and reduce tolerance to treatments.
- AIDS: It significantly impacts the quality of life and overall health of affected individuals.
- Heart Failure: Contributes to the deterioration of physical health and functional capacity.
- COPD: Accelerates muscle wasting and affects overall respiratory function.
Points to Remember
- Weight Loss: Significant, often unintended weight loss.
- Muscle Atrophy: Decrease in muscle mass, leading to weakness and functional impairment.
- Fatigue: Persistent tiredness and lack of energy.
- Inflammatory mediators, including TNF-α, IFN-γ, IL-1, and IL-6, play central roles in the development of cachexia.
Summary Table
| Aspect | Details |
|---|---|
| Definition | Syndrome with weight loss, muscle atrophy, and fatigue |
| Associated Diseases | Cancer, AIDS, heart failure, COPD |
| Key Mediators | TNF-α, IFN-γ, IL-1, IL-6 |
| Clinical Impact | Exacerbates disease, affects quality of life, and treatment tolerance |
This format provides a structured overview of cachexia, its pathophysiology, its impact on chronic diseases, and key points for easy reference.
